Clinical value of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis

F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is usually used to screen malignancy in patients with dermatomyositis (DM). Additionally, it is well known that FDG-PET/CT provides valuable information for evaluating the activity of several inflammatory diseases, such as sarcoidosis, atherosclerosis, inflammatory bowel disease and rheumatoid arthritis. Therefore, the objective of this study was to evaluate the clinical usefulness of FDG-PET/CT for the detection of inflammatory lesions and disease activity of both myopathy and interstitial lung disease (ILD) in DM patients. We measured the maximum standardized uptake value (SUVmax) in the muscles and lungs in 22 DM patients, and compared with magnetic resonance imaging (MRI) and high-resolution computed tomography (HRCT) findings in the same muscle and lung regions as well as with clinical findings. We found that the location of increased FDG uptake was nearly consistent with the region of ILD and myositis detected by HRCT or MRI, respectively. There was a significant positive correlation between lung HRCT score and SUVmax in each lung. Serum Krebs von den Lungen-6 levels also revealed significant positive correlation with total SUVmax of right and left lungs. Regarding FDG-PET/CT and myopathy, total SUVmax in the muscles was significantly correlated with serum cytokeratin levels. Our results suggest that FDG uptake (SUVmax) might be useful for not only the detection of malignant tumors, but also the evaluation of the location and activity of ILD and myositis in DM patients.

[1]  U. Tateishi,et al.  Deep-inspiration breath-hold 18F-FDG-PET/CT is useful for assessment of connective tissue disease associated interstitial pneumonia , 2016, Modern rheumatology.

[2]  Y. Tsushima,et al.  Role of F-18 FDG PET/CT in assessing IgG4-related disease with inflammation of head and neck glands , 2015, Annals of Nuclear Medicine.

[3]  F. Ernste,et al.  Cancer Risk in Dermatomyositis: A Meta-Analysis of Cohort Studies , 2015, American Journal of Clinical Dermatology.

[4]  K. Fujihara,et al.  Clinical values of FDG PET in polymyositis and dermatomyositis syndromes: imaging of skeletal muscle inflammation , 2015, BMJ Open.

[5]  S. Perlman,et al.  PET/CT imaging of inflammatory bowel disease. , 2013, Seminars in nuclear medicine.

[6]  Kotaro Suzuki,et al.  [18F]FDG uptake in proximal muscles assessed by PET/CT reflects both global and local muscular inflammation and provides useful information in the management of patients with polymyositis/dermatomyositis. , 2013, Rheumatology.

[7]  T. Fukuda,et al.  Detection of Inflammatory Lesions by F-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Polymyositis and Dermatomyositis , 2012, The Journal of Rheumatology.

[8]  A. Versari,et al.  F-Fluorodeoxyglucose positron emission tomography for the assessment of myositis : a case series , 2006 .

[9]  I. Lundberg,et al.  KL‐6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis , 2012, Journal of internal medicine.

[10]  M. Suga,et al.  Pneumocyte Biomarkers KL-6 and Surfactant Protein D Reflect the Distinct Findings of High-Resolution Computed Tomography in Nonspecific Interstitial Pneumonia , 2011, Respiration.

[11]  M. Horger,et al.  Whole-body MRI: a helpful diagnostic tool for juvenile dermatomyositis case report and review of the literature , 2009, Rheumatology International.

[12]  A. Alavi,et al.  Functional imaging of inflammatory diseases using nuclear medicine techniques. , 2009, Seminars in nuclear medicine.

[13]  A. Alavi,et al.  Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. , 2008, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  J. Vencovský,et al.  The role of MRI in the assessment of polymyositis and dermatomyositis. , 2007, Rheumatology.

[15]  I. D. Johnston,et al.  British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival , 2006, Thorax.

[16]  N. Müller,et al.  Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and nonsurvivors. , 2002, American journal of respiratory and critical care medicine.

[17]  R. Sontheimer Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? , 2002, Journal of the American Academy of Dermatology.

[18]  R. Strawderman,et al.  Clinical significance of histological classification of idiopathic interstitial pneumonia , 2002, European Respiratory Journal.

[19]  A. Nicholson,et al.  The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. , 2000, American journal of respiratory and critical care medicine.

[20]  A. Drop,et al.  Role of 18F-FDG PET/CT in the diagnosis of inflammatory and infectious vascular disease. , 2016, Nuclear medicine review. Central & Eastern Europe.

[21]  M. Isono,et al.  18F-FDG PET/CT useful for the early detection of rapidly progressive fatal interstitial lung disease in dermatomyositis. , 2012, Internal medicine.

[22]  N. Müller,et al.  Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality , 2011, European Radiology.

[23]  K P Offord,et al.  Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. , 1998, American journal of respiratory and critical care medicine.

[24]  Robert G. Cooper,et al.  Polymyositis and Dermatomyositis , 2022 .